Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting

por Lu, Yung-Hsin, Lu, Chung-Kuang, Chen, Chun-Hsien, Hsieh, Yung-Yu, Tung, Shui-Yi, Chen, Yi-Hsing, Yen, Chih-Wei, Tung, Wei-Lin, Chang, Kao-Chi, Chen, Wei-Ming, Lu, Sheng-Nan, Hung, Chao-Hung, Chang, Te-Sheng
Publicado 2022

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan

por Chang, Kao-Chi, Tung, Shui-Yi, Wei, Kuo-Liang, Shen, Chen-Heng, Hsieh, Yung-Yu, Chen, Wei-Ming, Chen, Yi-Hsing, Chen, Chun-Hsien, Yen, Chi-Wei, Xu, Huang-Wei, Tung, Wei-Lin, Hung, Chao-Hung, Lu, Sheng-Nan, Chang, Te-Sheng
Publicado 2021